{"entity":{"id":"hdac9","kind":"target","name":"HDAC9","aka":["histone deacetylase 9","Histone deacetylase 9","KIAA0744","HD7","HDAC7B"],"tldr":"HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.","summary":"Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.\n\nCIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Panobinostat, HDAC Inhibitor REC-2282, Vorinostat and Trichostatin A. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.34, clinical 0.95).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:14065","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14065"},{"label":"UniProt Q9UKV0","url":"https://www.uniprot.org/uniprotkb/Q9UKV0/entry"},{"label":"NCBI Gene 9734","url":"https://www.ncbi.nlm.nih.gov/gene/9734"},{"label":"Ensembl ENSG00000048052","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048052"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["breast-cancer","esophageal","non-hodgkin-lymphoma","multiple-myeloma","skin-cancer","glioblastoma","cutaneous-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.95; CIViC holds 3 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"HDAC9","role":["drug-target","biomarker","fusion-partner"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:14065","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14065","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9UKV0","url":"https://www.uniprot.org/uniprotkb/Q9UKV0/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene HDAC9","url":"https://civicdb.org/features/7704","note":"3 evidence items, 0 assertions, 2 variants; diseases: Glioblastoma, Breast Cancer, Oesophageal Cancer (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000048052","url":"https://platform.opentargets.org/target/ENSG00000048052/associations","note":"association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: plasma cell myeloma 0.56, non-Hodgkin lymphoma 0.58, skin cancer 0.51, primary cutaneous T-cell non-Hodgkin lymphoma 0.51 (GraphQL API, CC0)"}],"hgnc":"HGNC:14065","ensembl":"ENSG00000048052","uniprot":"Q9UKV0","entrez":"9734","biology":"Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Location: Nucleus (UniProt). Locus 7p21.1 (HGNC).","whereFound":["Breast cancer: CIViC evidence names this disease","Oesophageal cancer: CIViC evidence names this disease","Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908)","Multiple myeloma: Open Targets association 0.56 with plasma cell myeloma (MONDO_0009693)","Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)","Glioma & glioblastoma: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/hdac9/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}]}}